Marburg, Germany

Ernest-Guenter Afting

This inventor holds 2 USPTO granted patents. Top assignees: Behringwerke Aktiengesellschaft, Chiron Corporation. Active years: 1995-1996.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1995-1996

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Ernest-Guenter Afting

Introduction

Ernest-Guenter Afting is a notable inventor based in Marburg, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of peptide plasminogen activators. His work has led to advancements that improve the properties of natural tissue plasminogen activator.

Latest Patents

Afting holds 2 patents related to novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA). These patents describe compositions that exhibit enhanced specific activity, reduced inhibition by plasminogen activator inhibitors, and improved affinity to fibrin surfaces. Modifications to one or both of the N- or C-termini are key features of these innovations. The plasmids designated 1, 2, and 3 were deposited at the A.T.C.C. on December 20, 1985, and received designations 40214, 40215, and 40216, respectively.

Career Highlights

Throughout his career, Afting has worked with prominent companies such as Chiron Corporation and Behringwerke Aktiengesellschaft. His expertise in biochemistry has allowed him to contribute to significant advancements in the field.

Collaborations

Afting has collaborated with notable colleagues, including Nancy L. Haigwood and Guy T. Mullenbach. These partnerships have further enriched his research and innovations.

Conclusion

Ernest-Guenter Afting's contributions to the field of biochemistry, particularly through his patents on peptide plasminogen activators, highlight his role as an influential inventor. His work continues to impact the scientific community and advance medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…